Success Metrics

Completion Rate
0%(0/2)
Active Trials
6(60%)
Terminated
2(20%)

Phase Distribution

Ph phase_1
2
20%
Ph not_applicable
1
10%
Ph phase_2
7
70%

Phase Distribution

2

Early Stage

7

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
7(70.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

6

trials recruiting

Total Trials

10

all time

Status Distribution
Active(8)
Terminated(2)

Detailed Status

Recruiting5
Not yet recruiting2
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
6
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (20.0%)
Phase 27 (70.0%)
N/A1 (10.0%)

Trials by Status

not_yet_recruiting220%
recruiting550%
terminated220%
active_not_recruiting110%

Recent Activity

6 active trials
Showing 5 of 10
recruitingphase_2

PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy

NCT07463248
active_not_recruitingphase_2

Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer

NCT07635290
recruitingnot_applicable

PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer

NCT07607119
recruitingphase_1

NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer

NCT07595172
terminatedphase_2

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

NCT05846659
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07463248Phase 2

PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy

Recruiting
NCT07635290Phase 2

Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer

Active Not Recruiting
NCT07607119Not Applicable

PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer

Recruiting
NCT07595172Phase 1

NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer

Recruiting
NCT05846659Phase 2

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

Terminated
NCT07403877Phase 2

Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer

Not Yet Recruiting
NCT07291947Phase 1

PULSAR Combined With Immunotherapy and Chemotherapy

Recruiting
NCT05846646Phase 2

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

Terminated
NCT07005882Phase 2

Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy

Not Yet Recruiting
NCT06359275Phase 2

PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients

Recruiting

All 10 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
10